BRPI0513866A - composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação - Google Patents

composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação

Info

Publication number
BRPI0513866A
BRPI0513866A BRPI0513866-3A BRPI0513866A BRPI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A BR PI0513866 A BRPI0513866 A BR PI0513866A
Authority
BR
Brazil
Prior art keywords
microparticles
composition
inhalation device
pulmonary hypertension
treatment
Prior art date
Application number
BRPI0513866-3A
Other languages
English (en)
Inventor
Curtis Ruegg
Julian A Blair
Original Assignee
Cotherix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cotherix Inc filed Critical Cotherix Inc
Publication of BRPI0513866A publication Critical patent/BRPI0513866A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO, MICROPARTìCULAS, MéTODO PARA O TRATAMENTO DA HIPERTENSãO PULMONAR, E, DISPOSITIVO DE INALAçãO São expostas micropartículas compreendendo iloprost. Em algumas modalidades, as micropartículas são usadas para tratar hipertensão pulmonar. Dispositivos que compreendem as micropartículas são também usados. Terapias combinadas, que utilizam as micropartículas, são também providas.
BRPI0513866-3A 2004-07-26 2005-07-26 composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação BRPI0513866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59125304P 2004-07-26 2004-07-26
PCT/US2005/026449 WO2006014930A2 (en) 2004-07-26 2005-07-26 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation

Publications (1)

Publication Number Publication Date
BRPI0513866A true BRPI0513866A (pt) 2008-05-20

Family

ID=35169689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513866-3A BRPI0513866A (pt) 2004-07-26 2005-07-26 composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação

Country Status (13)

Country Link
US (1) US20060147520A1 (pt)
EP (1) EP1796653A2 (pt)
JP (1) JP2008507585A (pt)
KR (1) KR20070054644A (pt)
CN (1) CN101090714A (pt)
AU (1) AU2005269465A1 (pt)
BR (1) BRPI0513866A (pt)
CA (1) CA2574958A1 (pt)
IL (1) IL180851A0 (pt)
MX (1) MX2007000979A (pt)
NO (1) NO20071090L (pt)
RU (1) RU2007106714A (pt)
WO (1) WO2006014930A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906922A2 (en) * 2005-05-18 2008-04-09 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
US20080305176A1 (en) * 2006-01-24 2008-12-11 Biocompatibles Uk Limited Process For Loading Polymer Particles With Drug
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
WO2009103068A1 (en) 2008-02-15 2009-08-20 Life Technologies Corporation Methods and compositions for shearing of polymers by sonication
US8479728B2 (en) 2008-02-18 2013-07-09 Virginia Commonwealth University Effective delivery of nanoparticles and micrometer-sized pharmaceutical aerosols to the lung through enhanced condensational growth
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US20110311630A1 (en) * 2008-06-09 2011-12-22 Boehringer Ingelheim International Gmbh Novel embedment particles for inhalation
WO2009150120A1 (de) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Neue emulsionen zur herstellung von arzneimitteln
JP5681626B2 (ja) * 2008-07-14 2015-03-11 ポリーペイド リミテッドＰｏｌｙｐｉｄ Ｌｔｄ． 徐放性薬剤キャリア組成物
DE102008037324A1 (de) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
US20120177693A1 (en) * 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
EP2370068A4 (en) * 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
AU2010229730A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
JP2013500341A (ja) * 2009-07-27 2013-01-07 カーギル・インコーポレイテッド 高血圧症の予防または治療のためのエリスリトールの使用
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
SI2672957T1 (sl) 2011-02-07 2017-03-31 Scipharm Sarl Nova sestava za zdravljenje cistične fibroze
JP2014518842A (ja) 2011-02-25 2014-08-07 サウス ダコタ ステート ユニバーシティー ポリマーコンジュゲートタンパク質ミセル
TWI602568B (zh) 2011-04-26 2017-10-21 維克多瑞有限責任公司 以氣膠氣囊之伊洛前列素（ｉｌｏｐｒｏｓｔ）之投藥方法
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
CN104853744B (zh) * 2012-10-31 2018-01-19 维克多瑞有限责任公司 气溶胶化伊洛前列素的给药
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US11925628B2 (en) * 2015-06-30 2024-03-12 Shanghai Jiao Tong University Applications for nicardipine in preparing anti-lung cancer products
EP3402347B1 (en) * 2016-01-11 2022-06-29 Arizona Board of Regents on behalf of Arizona State University Ereptiospiration device for medicinal waxes, solids, biopolymers, or highly viscous oils, and cannabinoids
AU2017211410B2 (en) * 2016-01-29 2022-10-13 Mannkind Corporation Dry powder inhaler
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
DK3512495T3 (da) * 2016-09-15 2022-12-05 Camurus Ab Formuleringer af prostacyklinanaloger
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
KR20240119159A (ko) * 2018-09-14 2024-08-06 파모사 바이오팜 인코포레이티드 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
US20240299413A1 (en) 2020-08-07 2024-09-12 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration
WO2022036234A1 (en) * 2020-08-13 2022-02-17 Eicos Sciences, Inc. Subcutaneous or intramuscular injection formulations of iloprost
JP7728347B2 (ja) * 2020-12-22 2025-08-22 ラジオメーター・メディカル・アー・ペー・エス 抗血小板剤および水溶性マトリックス材料を含有する血液サンプラー
US20230263807A1 (en) * 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
CN121772928A (zh) 2023-07-18 2026-03-31 Btg国际股份有限公司 使用伊洛前列素用于治疗冻伤的方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466325A (en) * 1892-01-05 Hubert glaus
US2882271A (en) * 1959-04-14 Xcixcxh
BE578515A (pt) * 1958-05-07
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL137318C (pt) * 1964-06-09
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3773939A (en) * 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
BE795735A (fr) * 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
JPS55301A (en) * 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3048906A1 (de) * 1980-12-19 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4468972A (en) * 1982-04-19 1984-09-04 Universal Cooperatives, Inc. Flow meter with a motor driven impeller
EP0094159B1 (en) * 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
DE3306123A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4950680A (en) * 1983-03-31 1990-08-21 Board Of Governors Of Wayne State University Method and compositions for inhibition of tumor cell induced platelet aggregation
US4567175A (en) * 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US4672068A (en) * 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
ATE71622T1 (de) * 1985-07-29 1992-02-15 Santen Pharmaceutical Co Ltd Neue benzothiazinabkoemmlinge.
US4885284A (en) * 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
EP0302980B1 (fr) * 1987-08-03 1991-03-13 Laboratorios Delagrange S.A. 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5239993A (en) * 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
DE69322789T2 (de) * 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
ES2187038T3 (es) * 1997-07-03 2003-05-16 Elan Drug Delivery Ltd Glicosidos modificados, composiciones que los comprenden y procedimientos para su utilizacion.
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
JP2006501138A (ja) * 2002-02-07 2006-01-12 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー ドラッグデリバリーのための治療用ポリ無水物化合物
DE10253623B4 (de) * 2002-11-15 2006-03-09 Justus-Liebig-Universität Giessen Bioabbaubare kolloidale Partikel, insbesondere für pulmonale Applikationen

Also Published As

Publication number Publication date
AU2005269465A1 (en) 2006-02-09
RU2007106714A (ru) 2008-09-10
WO2006014930A3 (en) 2007-02-01
US20060147520A1 (en) 2006-07-06
CN101090714A (zh) 2007-12-19
IL180851A0 (en) 2007-07-04
KR20070054644A (ko) 2007-05-29
JP2008507585A (ja) 2008-03-13
MX2007000979A (es) 2007-07-11
NO20071090L (no) 2007-02-26
EP1796653A2 (en) 2007-06-20
WO2006014930A2 (en) 2006-02-09
CA2574958A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20071090L (no) Behandling av pulmonal hypertensjon ved inhalert iloprost med en mikropartikkelformulering.
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20092637L (no) Fremgangsmater for behandling
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
WO2005074913A3 (en) Compositions and methods for treating contracture
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2009079451A3 (en) Compositions and methods of promoting wound healing
NO20063171L (no) Endoparasitisidale sammensetninger for topisk anvendelse
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2006063215A3 (en) Methods and compositions for the treatment of pulmonary hypertension of the newborn
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EP1773363A4 (en) NGNA COMPOSITIONS AND APPLICATION PROCEDURES
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
EA200801296A1 (ru) Способ лечения метаболического синдрома

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO DE: COTHERIX, INC.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]